Overview

Safety and Pharmacokinetic Study of IMM0306 in Patients With Refractory or Relapsed CD20-positive B-cell Non-Hodgkin's Lymphoma (B-NHL)

Status:
Not yet recruiting

Trial end date:
2024-04-11

Target enrollment:

Participant gender:

Summary

The purpose of this study is to assess the safety and efficacy of IMM0306-02 in patients with refractory or relapsed CD20-positive B-cell Non-Hodgkin's Lymphoma (B-NHL).

Phase:

Phase 1

Details

Lead Sponsor:

ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd

Collaborator:

Worldwide Clinical Trials